Sugi Predict

Sugi Predict / Compounds / SCHEMBL1748047

SCHEMBL1748047

SCHEMBL1748047

COc1ccc2nc(Cl)[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.58
▸ TP53 P04637 4/20 0.58
▸ RAB9A P51151 4/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ HPGD P15428 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ KDM4E B2RXH2 1/20 0.58
▸ TSHR P16473 1/20 0.58
▸ NFKB1 P19838 1/20 0.58
▸ NFKB2 Q00653 1/20 0.58
▸ RELA Q04206 1/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ CYP2E1 P05181 10/20 0.56
▸ CYP2C8 P10632 10/20 0.56
▸ CYP2D6 P10635 10/20 0.56
▸ CYP2C9 P11712 10/20 0.56
▸ CYP2B6 P20813 10/20 0.56
▸ CYP2C19 P33261 10/20 0.56
▸ CYP1A2 P05177 9/20 0.56
▸ CYP3A4 P08684 9/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1193199 0.86 ALDH1A1 (0.48) NPC1TP53RAB9AALDH1A1HPGD
SCHEMBL5786932 0.83 NPC1 (0.52) NPC1TP53RAB9AALDH1A1HPGD
SCHEMBL9305034 0.81 CBFB (0.56) NPC1RAB9AALDH1A1HPGDCYP2E1
SCHEMBL9304850 0.81 NPC1 (0.61) NPC1TP53RAB9AALDH1A1HPGD
SCHEMBL3140572 0.81 ALDH1A1 (0.46) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL29991190 0.80 NPC1 (0.52) NPC1TP53RAB9AALDH1A1HPGD
SCHEMBL21800738 0.80 NPC1 (0.52) NPC1TP53RAB9AALDH1A1HPGD
SCHEMBL4371528 0.80 KDM4E (0.61) NPC1TP53RAB9AALDH1A1HPGD
SCHEMBL29439014 0.80 KDM4E (0.61) NPC1TP53RAB9AALDH1A1HPGD
SCHEMBL6627259 0.79 NPC1 (0.58) NPC1TP53RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116947812-A Preparation method of Esomeprazole magnesium degradation impurity 南京红太阳医药研究院有限公司 2023-10-27 — — CN claimed
US-20260042743-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES COUNCIL SCIENT IND RES (IN) 2026-02-12 — — US disclosed
CN-116947812-B Preparation method of Esomeprazole magnesium degradation impurity 南京红太阳医药研究院有限公司 2025-09-02 — — CN disclosed
CN-116947812-A Preparation method of Esomeprazole magnesium degradation impurity 南京红太阳医药研究院有限公司 2023-10-27 — — CN disclosed
CN-116947812-A Preparation method of Esomeprazole magnesium degradation impurity 南京红太阳医药研究院有限公司 2023-10-27 — — CN disclosed
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS UNIV CALIFORNIA (US) 2023-05-11 — — US disclosed
EP-4125861-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS The Regents of the University of California (US) 2023-02-08 — — EP disclosed
WO-2021203016-A2 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-07 — — WO disclosed
US-10174052-B2 Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2019-01-08 — — US disclosed
US-20170305929-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2017-10-26 — — US disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
US-6156758-A Antibacterial quinazoline compounds ISIS PHARMACEUTICALS, INC. (US) 2000-12-05 — — US disclosed
WO-2000071522-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS METHIONYL T-RNA SYNTHETASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 2000-11-30 — — WO disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed
EP-0239129-B1 HYDROQUINOLINE COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-09-25 — — EP disclosed
US-4963566-A ANTIULCER AGENT OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-10-16 — — US disclosed
US-4880815-A GASTRIC JUICE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-11-14 — — US disclosed
US-4738970-A Benzimidazolyl-thio-tetrahydroquinolines and anti-peptic ulcer compositions containing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-04-19 — — US disclosed
EP-0239129-A2 Hydroquinoline compounds, compositions containing same and processes for preparing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-09-30 — — EP disclosed
EP-0187977-A1 Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-07-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10174052-B2 Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands CHRNA7, CHRNA5, CHRNA2 NPC1 752/4885TP53 4443/4885RAB9A 479/4885
US-20170305929-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA2 NPC1 875/4885TP53 4407/4885RAB9A 530/4885
US-20230142739-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS HSPBP1, HSPA8, HSPH1 NPC1 3575/4885TP53 806/4885RAB9A 2291/4885
US-20260042743-A1 SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES ACE2, SARS1, NR3C2 NPC1 85/4885TP53 2863/4885RAB9A 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.